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Gastric carcinoma, or stomach cancer, is a major disease in the world today.  Although it 
only accounts for about 2% of all cancer cases in the United States, it is much more 
prevalent in nations such as Korea, Japan, Great Britain, South America, and Iceland.  
While the most common treatment for gastric carcinoma is surgery, there are 
chemotherapeutic alternatives including the application of doxorubicin, also known as 
Adriamycin®.   
 
However, as with nearly all chemotherapy drugs, doxorubicin causes dose-dependent 
toxicity that results in severe biological side effects and, potentially, death.  Many of the 
adverse effects of doxorubicin may be attributed to the fact that it is normally 
administered intravenously; thus, although the drug’s target is the stomach, the 
doxorubicin is systemically rampant.  Hence, we have developed a delivery system for 
doxorubicin that we hope will limit the drug’s action to the stomach alone.   
 
We begin with a means for encasing the doxorubicin inside two types of hydrogels whose 
diffusive properties vary depending on temperature and pH levels, such that diffusion 
may be maximized in the stomach and minimized at all other locations inside the 
gastrointestinal tract.  This original design was modeled as a 1-D radial line to represent 
the spherical shape of the pill.  After investigation, another design involving a hollowed 
out hemisphere was modeled and tested.  Results comparison shows that the second 
design scheme is superior to the first both in outward drug flux and in the amount of drug 
able to be delivered. 
 
Ultimately, results of the study showed that pH-dependent drug release can be attained at 
a steady and reliable rate, with significantly greater rates of release inside the stomach.  
However, we were unable to attain a clinically adequate amount of total doxorubicin 
release with our model designs.  Still, it may be possible to achieve medically useful 
results with pH-dependent drug delivery systems given certain technological 
improvements in the future. 
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Drug specificity is a complicated problem in medicine today.  Most drugs are ingested or 
intravenously released into the bloodstream, thus affecting the whole body.  Site-specific 
drugs usually rely on antibody/antigen interactions, but current technology on these drugs 
is limited.  We propose a drug encapsulation system that diffuses a specific drug based on 
pH and temperature changes in the body.  Our model drug for this study will be 
doxorubicin, which may effectively combat gastric carcinoma but also has the threat of 
causing dose-dependent toxicity.  The goal is to present a drug delivery system based on 
hydrogels whose diffusive properties vary depending on the pH and temperature of their 
surroundings such that their maximum diffusivity is attained inside the human stomach.  
Hence we hope to be able to reliably transport doxorubicin into the stomach while 
limiting drug release in other areas of the body. 
  
The most widely used method of doxorubicin application today is injection, which 
systemically disperses the drug throughout the body and leads to undesirable side effects 
including nausea, neutropenia, heart arrhythmias, congestive heart failure, dilated 
cardiomyopathy, and death.  Other attempts have been made at developing drug delivery 
systems to limit these ill effects, but all have their downsides.  For example, various 
species’ erythrocytes have been used as drug carriers, but doxorubicin tends to diffuse 
from these cells to plasma more quickly than desired, thereby defeating the purpose.  As 
a countermeasure to this, experimenters treated the erythrocytes with glutaraldehyde to 
successfully slow the doxorubicin release, but neglected to address the toxicity of 
glutaraldehyde as well as the possible adverse effects on the doxorubicin drug as a result 
of glutaraldehyde treatment.  These combined problems are inspiring pharmaceutical 
scientists to develop new synthetic forms of drug delivery that can help mitigate these 
undesirable effects while maximizing targeted drug delivery. 
  
We believe that our delivery method will be different because our encapsulating materials 
are fully biocompatible, and should not produce any unforeseen effects on the 
doxorubicin itself.  Furthermore, experimenters at Cornell University have already 
performed tests specifically with doxorubicin in order to determine the pH-dependency of 
its diffusion in dextran hydrogels, with positive results.  Therefore we feel that our 
models and their comparison may shed light into the area of synthetic hydrogel drug 
delivery and its applications in future research. 
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We will use Comsol Multiphysics to test our model designs of orally delivered hydrogel-
mediated doxorubicin diffusion in physiological human body conditions.  Our objectives 
are: 
 
•  To determine whether an appropriate dose of doxorubicin can be delivered.  This 
will show whether our model system is viable for doxorubicin delivery.  Rxlist 
gives the usual recommended dose for doxorubicin treatment as 60 to 75 mg/m
2, 
which translates to approximately 130 mg, or 2.39 x 10
-4 mol of drug, for a 
normal adult male. 
 
•  To determine whether there is a significant difference between drug release inside 
the stomach versus the rest of the body, particularly the intestines.  This will 
provide justification for our delivery system as opposed to the existing 
intravenous delivery system. 
 
•  Given the first two objectives, to achieve a steady and reliable release profile of 
doxorubicin inside the body.  This will work toward making the final product 
medically viable. 
 
Model Design I: 
 Three-Layered Hydrogel Sphere 
 
We will begin our approach to this problem by modeling the drug delivery vehicle as a 
sphere with three 1mm layers.  The innermost layer will be made of dextran hydrogel 
crosslinked with methacrylic anhydride at a degree of substitution (DS) of 0.24.  We 
chose DS = 0.24 because that value corresponded with the greatest difference in 
doxorubicin diffusivity in a study conducted by Kim and Chu (2000).  The diffusivity 
difference with varying pH comes from the expansion or collapse of the hydrogel matrix 
due to molecular interactions in the crosslinked fibers of the hydrogel.  Essentially, the 
pore size of the hydrogel increases with decreasing pH.  The work by Kim and Chu also 
suggested an initial concentration of 1 mg/mL (or 0.6897 mol/m
3) of doxorubicin.  The 
second layer will also be dextran-methacrylate hydrogel, but it would have no initial 
concentration of doxorubicin.  This second layer is designed to act as a barrier so that the 
drug will not all diffuse out of the capsule at once; rather, we want drug release to occur 
over a period of six hours.  This is approximately the amount of time that we estimate the 
spheres will remain inside the stomach.  The final outer layer would be made of a 
temperature-sensitive biodegradable hydrogel composed of poly(ethylene oxide) and 
poly(L-lactic acid).  A 2D representation of the spherical delivery system is presented in 
Figure 1 below: 
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Figure 1 - 2D Representation of Spherical Drug Delivery Capsule 
 
Our input model for Comsol is represented by the Figure 2 below: 
 
 
____________________________________________________________                  
  Drug-loaded dextran gel       Empty dextran gel                Empty polymer gel     
                   1mm                                           1mm                                               1mm             
Figure 2 - 1D Model of Drug Delivery Capsule for Comsol 
 
We were able to model our sphere in Comsol in 1D geometry by adjusting the standard 
governing equation and by using axisymetrical and insulating boundary conditions at the 
left and right ends, respectively.  To see our governing equation and boundary and initial 
conditions in greater detail, please refer to Appendix A. 
 
As previously mentioned, we attempted to simulate the physiological conditions of 
ingesting these spheres as closely as possible by assuming that the spheres would remain 
in the stomach for six hours before passing into the intestines.  We also assumed that the 
pH of the stomach would remain relatively constant at pH = 3.0, as opposed to the more 
basic intestines at approximately pH = 7.4.  This affected our choice of input parameters 
which are displayed in Table 1.   
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Spherical Design Input Parameters 
   pH = 3.0  pH = 7.4    
Initial Concentration
1 0.6897 0.6897  mol/m
3
Dextran-Methacrylate Hydrogel Diffusivity
1 1.972E-11 1.047E-11  m
2/s 
Polyethylene oxide Hydrogel Diffusivity
2 1.933E-11 1.933E-11  m
2/s 
1: Kim and Chu 2000; 2: Jeong, et al 1997, Verma 2005 
 
Our goal is to achieve reliable release of drug over the course of six hours at normal 
stomach conditions (temperature = 37°C, pH = 3.0) with a significantly lower rate of 
release at other values of temperature and pH. 
 
Model Design II: 
Dextran-Methacrylate Hemisphere 
 
Our second model is considerably different from the first.  Instead of dealing with a 
spherical hydrogel with diffusion from the outer spherical surface, we are now looking at 
a hemisphere with a hollowed center.  The center core is 1.0 mm in diameter with the 
outer hemisphere being 3.0 mm in diameter.  Drug is released from the exposed surface 
of the hollow center while the other surfaces are covered with a biocompatible, 
completely impermeable polymer layer such as polyetheretherketone (PEEK).  This can 
be more clearly seen in Figure 3, which maps out the geometry and dimensions of the 
second design.   
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(A) 
 
(B) 
 
Figure 3 – A) Cross-section cut from the side of the hemisphere drug delivery capsule.  
Note the impermeable outer layer and drug releasing divot.  B) The hemispherical design 
again emphasizing three dimensional aspects of the pill. 
 
The input parameters are modeled on the original design and literature by Kim and Chu, 
incorporating the initial value of 0.6897 mol/m
3 along with the same values for Dextran 
hydrogel diffusivity at pH = 3.0 and pH = 7.4 (Table 2).   
 
Table 2 – Model Design II Input Parameters 
Hemispherical Design Input Parameters 
   pH = 3.0  pH = 7.4    
Initial Concentration
1 0.6897 0.6897  mol/m
3
Dextran-Methacrylate Hydrogel Diffusivity
1 1.972E-11 1.047E-11  m
2/s 
1: Kim and Chu 2000 
pH-Dependent Drug Delivery Systems       8We were able to model this geometry in Comsol as a 2-D quarter circle with symmetry 
around the axis penetrating the hollowed center.  The boundary conditions used are as 
follows: 
1) 
t
cA
∂
∂
= 0 at r = 1.5 mm and the top edge 
2)  cA = 0 at r = 0.5 mm because we assume instant drug removal 
 
3)  Our model is axi-symmetric around the hollow center 
 
 
Figure 4 – 2D Axisymmetric Profile for Hemispherical Model in Comsol 
 
As mentioned in our Design Objectives, our model design was intended to deliver an 
adequate amount of doxorubicin to the patient, as well as to deliver that drug in a 
relatively steady stream with respect to time.  We suspected that the first objective would 
not be achieved, so we attempted to compensate by reaching for the greatest ratio of drug 
released per unit of drug delivery particle volume. 
 
From our previous modeling with the multi-layered drug delivery sphere, we guessed at 
an initial radius of 1mm for the dextran-methacrylate hydrogel layer.  This translates into 
a sphere of total radius 1.5mm, with a 0.5mm-radius dimple in the center.  To verify these 
results we ran a mesh convergence that may be viewed in Appendix B. 
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Model Design I – Three-Layered Hydrogel Sphere 
 
The objective of the modeling experiment was to show the behavior of a three-layered 
hydrogel sphere and its ability to deliver doxorubicin to the stomach in order to act as a 
safer and more selective form of chemotherapy.  Figure 5 below shows the average 
concentration vs. radial distance from the center of the sphere.  
 
 
Figure 5 - Average Concentration vs. Radial Distance (Time = 6 hr) 
 
This graph portrays how the average concentration decreases more sharply in the dextran-
methacrylate layers (0 < x < 2mm) and levels off in the hydrogel polymer layer.  This is 
expected because the protective hydrogel polymer layer has an 84% larger diffusivity 
constant than the dextran layer.  This also portrays our boundary condition of zero 
concentration at the surface, assuming immediate removal of the drug once free of the gel 
sphere. 
 
Another factor we modeled was the total amount of drug released from the modeled 
system plotted against a time variable.  Figure 6 and Table 3 below shows the amount of 
doxorubicin released for the two different pH levels that we were considering.  It is 
pH-Dependent Drug Delivery Systems       10apparent that at the lower pH of the stomach, more drug is released due to the chemical 
properties of the gel material.  The higher pH of the small intestine shows a much lower 
amount of drug released.  Over a period of 6 hours, the amount of drug released in the pH 
= 3.0 system is 3.57 times larger than that released in the pH = 7.4 system. 
Total Doxorubicin Contained In Hydrogels at Stomach Temperature and pH
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Figure 6 – Model Design I Total Doxorubicin Released vs. Time (pH = 3.0 & pH=7.4) 
 
Table 3 – Doxorubicin Released Over Time From Model Design I 
  Stomach pH  Intestinal (Systemic) pH 
Time (hrs) 
Drug Remaining 
(mol) 
Drug Released 
(mol) 
Drug Remaining 
(mol) 
Drug Released 
(mol) 
0  2.89E-09 0.00E+00 2.89E-09 0.00E+00
1  2.89E-09 0.00E+00 2.89E-09 3.00E-15
2  2.89E-09 5.00E-14 2.89E-09 6.62E-13
3  2.89E-09 9.97E-13 2.88E-09 8.28E-12
4  2.88E-09 5.98E-12 2.85E-09 3.57E-11
5  2.87E-09 2.06E-11 2.80E-09 9.11E-11
6  2.84E-09 4.87E-11 2.71E-09 1.74E-10
 
Problems arise with this design including non-linear transient drug release along with a 
very small amount of total drug released.  A linear rate for drug release is desirable 
because it allows the release mechanism to stay in check and be monitored more easily 
by physicians.  As seen in Figure 6, the release rate increases exponentially and shows 
possible problems with sudden and delayed dosage.  This can be dangerous due to the 
extreme bio-toxicity of doxorubicin.  A sharp sudden dose could damage the stomach 
because of too high a concentration.  It could also lead to problems with the duodenum 
pH-Dependent Drug Delivery Systems       11and small intestine because the release is delayed until the end of the six hour period.  
Furthermore, the overall amount of doxorubicin released stands at 1.74 x 10
-10 moles 
after six hours in the stomach, which corresponds to only 9.46 x 10
-5 mg, or 7.27 x 10
-5 
percent of an effective dose. 
 
Model Design II – Dextran-Methacrylate Hemisphere 
 
Our second design modeled the release of doxorubicin from a single dextran-
methacrylate hydrogel layer within a 3 mm OD hemisphere with a 1 mm OD divot in the 
core.  To do a true comparison between this and the original spherical model, we plotted 
the amount of drug released versus time, seen in Figure 7.  This plot can be compared to 
the data in Figure 6 to see how our models differ. 
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Figure 7 - Model Design II Total Doxorubicin Released vs. Time (pH = 3.0 & pH=7.4) 
 
As shown in Figure 7, the total amount of drug released for the hemispherical model is 
twenty times larger than that of the spherical multilayer design (3.35 x 10
-9 mol versus 
1.74 x 10
-10 mol).  This is a vast improvement, though still only 0.0014% of an effective 
dose.  The major quality of the second design is that the rate of drug release becomes 
linear after the first hour in the pH = 3.0 setting.  This is optimal when compared to the 
exponential growth of the original design because it is easier to predict and control the 
drug release behavior within the body.   
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  Stomach pH  Intestinal (Systemic) pH 
Time 
(hrs) 
Drug 
Remaining 
(mol) 
Drug 
Released 
(mol) 
Total Drug 
Released (mol) 
Drug 
Remaining 
(mol) 
Drug 
Released 
(mol) 
Total Drug 
Released 
(mol) 
0 4.69E-09 0.00E+00  0.00E+00 4.69E-09 0.00E+00 0.00E+00
1 4.21E-09 4.74E-10  9.49E-10 4.38E-09 3.14E-10 6.28E-10
2 3.93E-09 7.63E-10  1.53E-09 4.20E-09 4.94E-10 9.88E-10
3 3.67E-09 1.02E-09  2.04E-09 4.04E-09 6.51E-10 1.30E-09
4 3.44E-09 1.25E-09  2.50E-09 3.89E-09 7.96E-10 1.59E-09
5 3.22E-09 1.47E-09  2.94E-09 3.76E-09 9.33E-10 1.87E-09
6 3.01E-09 1.68E-09  3.35E-09 3.62E-09 1.06E-09 2.13E-09
 
In order to check how well-optimized the 1.5mm-radius size was for the hemispheric 
drug delivery system, we contrasted it with two other sizes: one larger (3mm-radius) and 
one smaller (0.6mm-radius).  The larger hemisphere kept a linear drug release profile and 
delivered more doxorubicin overall, but had a lower drug release to volume ratio.  The 
smaller hemisphere had a considerably larger drug release to volume ratio, but had a 
more curved drug release profile, thus defeating the purpose of the revised geometry.  
Hence, we concluded that the 1.5mm-radius hemisphere was adequately appropriate for 
the final model. 
 
Table 5 – Size Optimization 
Total 
Radius 
Initial Drug 
(mol) 
Final Drug 
(mol) 
Drug Released 
(mol) 
Total Drug 
Released (mol) 
Drug Release per 
Volume Ratio 
0.6 mm  3.00E-10  2.35E-11 4.67E-09 9.33E-09 1.03E-08
1.5 mm  4.69E-09  3.01E-09 1.68E-09 3.35E-09 2.37E-10
3 mm  3.75E-08  3.25E-08 4.99E-09 9.99E-09 8.83E-11
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Figure 8 - 0.6mm-Radius Hemispheric Drug Release Over Time 
 
Once we came to the point of deciding on a 1.5 mm radius hemisphere, we conducted the 
simulation and solved for the solution at t = 21600 seconds.  We obtained a contour plot 
to show the amount of drug as one moves to the center of the sphere toward the release 
edge. 
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Figure 9 – Concentration Contour Plot of Model Design II 
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The following sensitivity analysis portrays how the amount of drug released varies at 
difference values of initial concentration, diffusivity, and maximum mesh size.  The 
diffusivity and initial concentration values are set to be at 75%, 100%, and 125% of the 
design parameters. The values used are shown in the table after the graph. 
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Figure 10 - Sensitivity Analysis plot 
 
Table 6 – Sensitivity Analysis data 
Initial Concentration (mol/m
3)  Drug Released (mol)  Percent Change  
0.5173 2.26E-09  -20.0 
0.6897 3.01E-09    0 
0.8621 3.76E-09  24.7 
       
Dextran Methacrylate Diffusivity 
(m
2/s)  Drug Released (mol)  Percent Change 
4.93E-12 6.24E-10  -62.7 
1.972E-11 1.67633E-09    0 
4.437E-11 2.87E-09  71.2 
 
It is apparent in Figure 10 that varying the initial concentration and the diffusivity values 
produce similar trends in the amount of drug that is released from the spherical gelatin 
capsule.  Increasing the diffusivity allows more of the drug to be released. This can be 
pH-Dependent Drug Delivery Systems       16supported by a higher temperature or a lower pH than is defined in our original design 
parameters of 37ºC and 3.0 pH. 
 
Initial Concentration 
 
As shown in Figure 11, initial concentration has the weakest influence on the amount of 
drug which can be released from the hydrogel sphere.  When we decrease the initial 
concentration to 75% of the original value (0.5173 mol/m
3), we see a 20% decrease in the 
amount of released drug.  Similarly, we are presented with approximately a 24.7% 
increase in the drug released when we simulated the drug release at the higher initial 
concentration.   
 
We can conclude that the initial concentration shows little room for improvement, 
because the same percentage change in drug concentration must be added to obtain the 
same percentage change in drug released.  Therefore, if we double the initial 
concentration we shall subsequently double the drug released.   
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Figure 11 - Initial Concentration vs. Drug Release (Hemisphere) 
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The diffusivity change in our dextran methacrylate layer shows the biggest increases as 
presented thus far.  When the diffusivity value is increased by 125% of the original 
(4.437 x 10
-11 m
2/s) we see a 71% increase in the amount of drug released. Reducing the 
diffusivity to 4.93 x 10
-12 m
2/s caused a 63% decrease in the amount of drug released.  
This is the layer containing the drug and therefore has the highest effect on the 
doxorubicin released due to the changes in diffusivity.  The detailed correlation is shown 
in the following graph with a linear fit to detail the slope of the regression. 
Drug Release vs. Dextran-Methacrylate Diffusivity
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Figure 12 - Drug Release vs. Dextran-Methacrylate Diffusivity (Hemisphere) 
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The first criteria we took into account for our design were health and safety.  Currently, 
doxorubicin is widely used in chemotherapy, but doses above 550 mg/m
2 can be lethal.  
The drug is typically injected intravenously, so this has not yet been a problem in 
treatment.  Our capsule is administered orally, though, so we needed to ensure that the 
drug had a constant flux that did not exceed the threshold dosage.  We also designed our 
drug to only be active in the low pH of the stomach to reduce side effects that come with 
intravenous treatment, but further testing must be done with our encapsulated drug to 
determine new side effects. 
 
Ethical considerations must also be taken into account when testing our product.  Animal 
testing will be the first phase of testing, and although this brings many ethical debates on 
its own, human testing will take the most consideration.  Because this is a drug that treats 
cancer, human lives are at stake.  We must be able to prove that our capsule delivers the 
drug as effectively or better than the intravenous treatment for it to be tested at all.  We 
expect our simulations and future animal testing will ensure that this is true.  
 
Other design criteria which we took into account were economics, manufacturability, and 
sustainability.  According to Biocompare.com, the price for doxorubicin is currently 
listed at $109 per 10 mg.  We expect the price of our encapsulated drug to be comparable, 
and the overall treatment will be more economically favorable for the consumer because 
it does not involve any extra costs that come with intravenous treatments and hospital 
visits.  The manufacturing will include technology similar to other pill producing 
processes, which mainly involves the photopolymerization reactions utilized when 
making our hydrogels.  Our research has found minimal environmental impact from 
photopolymerization.   Furthermore, the shelf life of our product will be long because the 
capsule is designed only to be active at body temperature.  Finally, our product will be 
sustainable for very long because doxorubicin has been long-established and widely used 
as an effective drug in cancer treatment. 
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Our model designs saw both success and failure with respect to our original Design 
Objectives.  Model Design I, the three-layered hydrogel spheres, was inadequate in that it 
failed to deliver an appropriate amount of doxorubicin in a single dose and yielded an 
inconsistent level of drug release over time.  It did succeed in achieving a significantly 
higher doxorubicin release in the stomach than in the intestines and systemic circulation.  
Model Design II, the dextran-methacrylate hemispheres, provided a significantly greater 
amount of total drug released (though still not a complete dose) and also had a 
considerably greater amount of outward flux in the stomach pH conditions than in the 
systemic pH conditions.  Furthermore, Model Design II improved on Model Design I by 
providing a nearly linear drug release profile over the six hours of simulation. 
 
Through this study, we have obtained theoretical, though not yet experimental, evidence 
that it is indeed possible to have a drug delivery system that can specifically target the 
stomach while withholding drug from the rest of the body.  We have shown that such 
drug release can occur at a controlled, steady rate given the correct choice of geometry.  
However, our study also suggests that our particular system of doxorubicin delivery via 
dextran-methacrylate hydrogel carriers is not adequate for the task.  The amount of drug 
delivered in a realistic time frame is simply not enough to have any worthwhile effect on 
gastric carcinoma in a typical patient. 
 
Thus, our design recommendations must focus on making improvements on the raw 
amount of drug that may be released from our delivery particles.  One such improvement 
could be the development of a new type of hydrogel (or other substance) that could retain 
the pH sensitivity of dextran-methacrylate while also being able to hold a greater initial 
concentration of doxorubicin or analogous drug.  Otherwise, new carrier substrates could 
be created to hold similar initial concentrations of drug, but with greater overall 
diffusivity values so that greater proportions of stored drug could be released in the given 
time period.  One final improvement that could be made in this field would be an 
experimental analysis of how much doxorubicin would be necessary for gastric 
carcinoma treatment if administered inside the stomach.  Since we only had data dealing 
with systemic intravenous application of the drug, we had to assume that the total 
amounts that we came up with were inadequate; yet, it is possible that the total amount 
needed could be significantly less given stomach lining absorption.  
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Model Design I – Three-Layered Hydrogel Sphere 
 
The overall Governing Equation for mass transfer in a sphere is the following: 
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We can eliminate the generation term because there is no drug generation within the 
nanoparticle.  Furthermore, we can eliminate the convection term because none exists 
within the particle.  Lastly, we can ignore diffusion elements in the θ and φ directions 
because our purpose is to model outward flow.  Thus, the simplified Governing Equation 
is as follows: 
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The Boundary Conditions that we will use are as follows: 
 
1.  Drug concentration everywhere outside of the particle is equal to zero. 
  0 200 = = r A c  
2.  Drug flux is equal to zero at r = 0. 
  0 0 =
∂
∂
= x
A
r
c
,  0 0 =
∂
∂
= y
A
r
c
 
 
The Initial Conditions are: 
 
1.  Drug concentration inside the core is equal to the initial concentration 0.6897 mol/m
3: 
  6897 . 0 50 = ≤ r A c mol/m
3 
2.  Drug concentration everywhere else is equal to zero: 
  0 50 = ; r A c  
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Model Design II – Dextran-Methacrylate Hemisphere 
 
Direct (UMFPACK) a linear system solver, was used to solve the algebraic equations. 
 
Problem Statement 
 Description 
Geometry Type  2-D 
Temperature 
Dependence 
Problem Dependent on Temperature 
Simulation Type  Transient: Concern with Amount of Drug 
Delivered over a period of time 
Time Dependent  Problem dependent on Time 
Flow Type  No Fluid Flow, No Momentum 
Convective Term  No Convection  
Surface Type  Geometry is fixed 
Flow Regime  Drug is Incompressible 
 
Time Integration Statement 
Time Integration  Description 
Time Step Algorithm  Increments of time is unchanging 
Start Time  0 
End Time  21600 
Time Step  60 
Number of Time Steps  360 
 
Parameters 
Parameter  Value
Times 0:60:21600
Relative tolerance  0.01
Absolute tolerance  0.0010
Times to store in output Specified Times
Time steps taken by solver Free
Manual tuning of step size  N/A
Initial time step N/A
Maximum time step N/A
Maximum BDF order 5
Singular mass matrix  Maybe
Consistent initialization of DAE systems Backward Euler
Error estimation strategy Include  Algebraic
 
Boundary Settings 
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Style  mol/m3  {0,{0,0,0}} 
 
 
Subdomain Settings 
Subdomain   1 
Diffusion coefficient (D)  m
2s 1.972e-11   
Time-scaling coefficient (Dts)  1 1 
Concentration  mol/m
3 0.6897 
 
Element Mesh: Model Design II – Dextran-Methacrylate Hemisphere 
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Figure 13 - 1.5mm-Radius Hemispheric Mesh 
 
Since there is a negligible (<<0.01%) change between the last two points of the 
convergence, we decided to stay with the third value, which had 2184 elements.  The 
actual structured mesh can be seen below and works well for the Comsol model. 
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Figure 14 - Mesh for the Hemispheric Geometry 
 
Note: Only Model Design II is featured here because it is our final design 
recommendation.  The Comsol data and mesh information for Model Design I was 
discarded due to of its ultimate triviality. 
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